{"id":"https://openalex.org/W2331462641","doi":"https://doi.org/10.1055/s-0031-1296600","title":"Improved Oral Bioavailability of Anti-HIV Agent N'-[2-(2-Thiophene)ethyl]-NT-[2-(5-bromopyridyl)]-thiourea (HI-443) in a Novel Lipophilic Formulation","display_name":"Improved Oral Bioavailability of Anti-HIV Agent N'-[2-(2-Thiophene)ethyl]-NT-[2-(5-bromopyridyl)]-thiourea (HI-443) in a Novel Lipophilic Formulation","publication_year":2011,"publication_date":"2011-12-21","ids":{"openalex":"https://openalex.org/W2331462641","doi":"https://doi.org/10.1055/s-0031-1296600","mag":"2331462641","pmid":"https://pubmed.ncbi.nlm.nih.gov/17469651"},"language":"en","primary_location":{"id":"doi:10.1055/s-0031-1296600","doi":"https://doi.org/10.1055/s-0031-1296600","is_oa":false,"landing_page_url":"https://doi.org/10.1055/s-0031-1296600","pdf_url":null,"source":{"id":"https://openalex.org/S132758211","display_name":"Arzneimittelforschung","issn_l":"0004-4172","issn":["0004-4172","1616-7066"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core"],"host_organization":"https://openalex.org/P4310320000","host_organization_name":"Thieme Medical Publishers (Germany)","host_organization_lineage":["https://openalex.org/P4310320000"],"host_organization_lineage_names":["Thieme Medical Publishers (Germany)"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Arzneimittelforschung","raw_type":"journal-article"},"volume":null,"type":"article","is_traditional":true,"indexed_in":["crossref","pubmed"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5091381226","display_name":"Fatih Mehmet Uckun","orcid":"https://orcid.org/0000-0001-9334-183X","observed_orcids":["https://orcid.org/0000-0001-9334-183X"]},"institutions":[{"id":"https://openalex.org/I4210120419","display_name":"Paradigm Pharmaceuticals (United States)","ror":"https://ror.org/02krbtc48","country_code":"US","type":"company","lineage":["https://openalex.org/I4210120419"]}],"countries":["US"],"is_corresponding":true,"raw_author_name":"Fatih Uckun","raw_affiliation_strings":["Paradigm Pharmaceuticals"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Paradigm Pharmaceuticals","institution_ids":["https://openalex.org/I4210120419"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5064317928","display_name":"Douglas H. Erbeck","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210110869","display_name":"Parker Hughes Cancer Center","ror":"https://ror.org/01ahys275","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I4210110869"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Douglas Erbeck","raw_affiliation_strings":["Parker Hughes Institute"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Parker Hughes Institute","institution_ids":["https://openalex.org/I4210110869"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5041574272","display_name":"Heather Tibbies","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210120419","display_name":"Paradigm Pharmaceuticals (United States)","ror":"https://ror.org/02krbtc48","country_code":"US","type":"company","lineage":["https://openalex.org/I4210120419"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Heather Tibbies","raw_affiliation_strings":["Paradigm Pharmaceuticals"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Paradigm Pharmaceuticals","institution_ids":["https://openalex.org/I4210120419"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5111972691","display_name":"Sanjive Qazi","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210110869","display_name":"Parker Hughes Cancer Center","ror":"https://ror.org/01ahys275","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I4210110869"]},{"id":"https://openalex.org/I4210120419","display_name":"Paradigm Pharmaceuticals (United States)","ror":"https://ror.org/02krbtc48","country_code":"US","type":"company","lineage":["https://openalex.org/I4210120419"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Sanjive Qazi","raw_affiliation_strings":["Paradigm Pharmaceuticals","Parker Hughes Institute"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Paradigm Pharmaceuticals","institution_ids":["https://openalex.org/I4210120419"]},{"raw_affiliation_string":"Parker Hughes Institute","institution_ids":["https://openalex.org/I4210110869"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5048956276","display_name":"Taracad K. Venkatachalam","orcid":"https://orcid.org/0000-0001-9747-1105","observed_orcids":["https://orcid.org/0000-0001-9747-1105"]},"institutions":[{"id":"https://openalex.org/I4210120419","display_name":"Paradigm Pharmaceuticals (United States)","ror":"https://ror.org/02krbtc48","country_code":"US","type":"company","lineage":["https://openalex.org/I4210120419"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Taracad Venkatachalam","raw_affiliation_strings":["Paradigm Pharmaceuticals"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Paradigm Pharmaceuticals","institution_ids":["https://openalex.org/I4210120419"]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":2,"corresponding_author_ids":["https://openalex.org/A5091381226"],"corresponding_institution_ids":["https://openalex.org/I4210120419"],"apc_list":null,"apc_paid":null,"fwci":0.0,"has_fulltext":false,"cited_by_count":3,"citation_normalized_percentile":{"value":0.23416511,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":null,"biblio":{"volume":"57","issue":"03","first_page":"164","last_page":"170"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10526","display_name":"HIV/AIDS drug development and treatment","score":0.5889000296592712,"subfield":{"id":"https://openalex.org/subfields/2725","display_name":"Infectious Diseases"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10526","display_name":"HIV/AIDS drug development and treatment","score":0.5889000296592712,"subfield":{"id":"https://openalex.org/subfields/2725","display_name":"Infectious Diseases"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10256","display_name":"Drug Solubulity and Delivery Systems","score":0.3434999883174896,"subfield":{"id":"https://openalex.org/subfields/3003","display_name":"Pharmaceutical Science"},"field":{"id":"https://openalex.org/fields/30","display_name":"Pharmacology, Toxicology and Pharmaceutics"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T10920","display_name":"Advanced Drug Delivery Systems","score":0.014999999664723873,"subfield":{"id":"https://openalex.org/subfields/3003","display_name":"Pharmaceutical Science"},"field":{"id":"https://openalex.org/fields/30","display_name":"Pharmacology, Toxicology and Pharmaceutics"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/non-nucleoside-reverse-transcriptase-inhibitors","display_name":"non-nucleoside reverse transcriptase inhibitors","score":0.8840000033378601},{"id":"https://openalex.org/keywords/oral-bioavailability","display_name":"oral bioavailability","score":0.8690000176429749},{"id":"https://openalex.org/keywords/oleic-acid","display_name":"oleic acid","score":0.9309999942779541},{"id":"https://openalex.org/keywords/thiourea-derivatives","display_name":"thiourea derivatives","score":0.503000020980835},{"id":"https://openalex.org/keywords/anti-hiv-agents","display_name":"anti-HIV agents","score":0.6859999895095825},{"id":"https://openalex.org/keywords/pharmacokinetics","display_name":"pharmacokinetics","score":0.9879999756813049},{"id":"https://openalex.org/keywords/toxicity-profile","display_name":"toxicity profile","score":0.5690000057220459},{"id":"https://openalex.org/keywords/systemic-exposure","display_name":"systemic exposure","score":0.49300000071525574}],"concepts":[{"id":"https://openalex.org/C181389837","wikidata":"https://www.wikidata.org/wiki/Q461809","display_name":"Bioavailability","level":2,"score":0.9628883004188538},{"id":"https://openalex.org/C2780538656","wikidata":"https://www.wikidata.org/wiki/Q528995","display_name":"Thiourea","level":2,"score":0.7894200086593628},{"id":"https://openalex.org/C185592680","wikidata":"https://www.wikidata.org/wiki/Q2329","display_name":"Chemistry","level":0,"score":0.7096540331840515},{"id":"https://openalex.org/C112705442","wikidata":"https://www.wikidata.org/wiki/Q323936","display_name":"Pharmacokinetics","level":2,"score":0.6858017444610596},{"id":"https://openalex.org/C98274493","wikidata":"https://www.wikidata.org/wiki/Q128406","display_name":"Pharmacology","level":1,"score":0.6425279378890991},{"id":"https://openalex.org/C2779953032","wikidata":"https://www.wikidata.org/wiki/Q305364","display_name":"Thiophene","level":2,"score":0.586374819278717},{"id":"https://openalex.org/C2777351918","wikidata":"https://www.wikidata.org/wiki/Q421559","display_name":"Reverse-transcriptase inhibitor","level":5,"score":0.5536240935325623},{"id":"https://openalex.org/C2776543447","wikidata":"https://www.wikidata.org/wiki/Q28734","display_name":"Nucleoside","level":2,"score":0.4575248956680298},{"id":"https://openalex.org/C2777056448","wikidata":"https://www.wikidata.org/wiki/Q285166","display_name":"Oral administration","level":2,"score":0.44307392835617065},{"id":"https://openalex.org/C29730261","wikidata":"https://www.wikidata.org/wiki/Q274160","display_name":"Toxicity","level":2,"score":0.41241228580474854},{"id":"https://openalex.org/C156719811","wikidata":"https://www.wikidata.org/wiki/Q28774","display_name":"Reverse transcriptase","level":4,"score":0.2588040828704834},{"id":"https://openalex.org/C71240020","wikidata":"https://www.wikidata.org/wiki/Q186011","display_name":"Stereochemistry","level":1,"score":0.2290724217891693},{"id":"https://openalex.org/C55493867","wikidata":"https://www.wikidata.org/wiki/Q7094","display_name":"Biochemistry","level":1,"score":0.1934642791748047},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.1679687798023224},{"id":"https://openalex.org/C178790620","wikidata":"https://www.wikidata.org/wiki/Q11351","display_name":"Organic chemistry","level":1,"score":0.140701025724411},{"id":"https://openalex.org/C67705224","wikidata":"https://www.wikidata.org/wiki/Q11053","display_name":"RNA","level":3,"score":0.054873526096343994},{"id":"https://openalex.org/C104317684","wikidata":"https://www.wikidata.org/wiki/Q7187","display_name":"Gene","level":2,"score":0.0}],"mesh":[{"descriptor_ui":"D000818","descriptor_name":"Animals","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D001682","descriptor_name":"Biological Availability","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D001772","descriptor_name":"Blood Cell Count","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D002626","descriptor_name":"Chemistry, Pharmaceutical","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D005079","descriptor_name":"Excipients","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D005260","descriptor_name":"Female","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D008807","descriptor_name":"Mice, Inbred BALB C","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D011725","descriptor_name":"Pyridines","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":true},{"descriptor_ui":"D011725","descriptor_name":"Pyridines","qualifier_ui":"Q000493","qualifier_name":"pharmacokinetics","is_major_topic":true},{"descriptor_ui":"D011725","descriptor_name":"Pyridines","qualifier_ui":"Q000633","qualifier_name":"toxicity","is_major_topic":false},{"descriptor_ui":"D013890","descriptor_name":"Thiourea","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":false},{"descriptor_ui":"D013890","descriptor_name":"Thiourea","qualifier_ui":"Q000031","qualifier_name":"analogs & derivatives","is_major_topic":true},{"descriptor_ui":"D013890","descriptor_name":"Thiourea","qualifier_ui":"Q000493","qualifier_name":"pharmacokinetics","is_major_topic":false},{"descriptor_ui":"D013890","descriptor_name":"Thiourea","qualifier_ui":"Q000633","qualifier_name":"toxicity","is_major_topic":false},{"descriptor_ui":"D018894","descriptor_name":"Reverse Transcriptase Inhibitors","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":true},{"descriptor_ui":"D018894","descriptor_name":"Reverse Transcriptase Inhibitors","qualifier_ui":"Q000493","qualifier_name":"pharmacokinetics","is_major_topic":true},{"descriptor_ui":"D018894","descriptor_name":"Reverse Transcriptase Inhibitors","qualifier_ui":"Q000633","qualifier_name":"toxicity","is_major_topic":false},{"descriptor_ui":"D019540","descriptor_name":"Area Under Curve","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D051379","descriptor_name":"Mice","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false}],"locations_count":2,"locations":[{"id":"doi:10.1055/s-0031-1296600","doi":"https://doi.org/10.1055/s-0031-1296600","is_oa":false,"landing_page_url":"https://doi.org/10.1055/s-0031-1296600","pdf_url":null,"source":{"id":"https://openalex.org/S132758211","display_name":"Arzneimittelforschung","issn_l":"0004-4172","issn":["0004-4172","1616-7066"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core"],"host_organization":"https://openalex.org/P4310320000","host_organization_name":"Thieme Medical Publishers (Germany)","host_organization_lineage":["https://openalex.org/P4310320000"],"host_organization_lineage_names":["Thieme Medical Publishers (Germany)"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Arzneimittelforschung","raw_type":"journal-article"},{"id":"pmid:17469651","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/17469651","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Arzneimittel-Forschung","raw_type":"Journal Article"}],"best_oa_location":null,"sustainable_development_goals":[{"display_name":"Good health and well-being","score":0.9537000060081482,"id":"https://metadata.un.org/sdg/3"}],"study_designs":[],"awards":[{"id":"https://openalex.org/G1190109229","display_name":"HI-443 as a Potent Anti-HIV Agent","funder_award_id":"R43AI052633","funder_id":"https://openalex.org/F4320337355","funder_display_name":"National Institute of Allergy and Infectious Diseases"}],"funders":[{"id":"https://openalex.org/F4320337355","display_name":"National Institute of Allergy and Infectious Diseases","ror":"https://ror.org/043z4tv69"}],"has_content":{"pdf":false,"grobid_xml":false},"content_urls":null,"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W2323774962","https://openalex.org/W2330399890","https://openalex.org/W2328870268","https://openalex.org/W2314351573","https://openalex.org/W153672433","https://openalex.org/W2011382157","https://openalex.org/W284690666","https://openalex.org/W2021814495","https://openalex.org/W2011423759","https://openalex.org/W2149148148"],"abstract_inverted_index":{"N'-[2-(2-Thiophene)ethyl]-N'-[2-(5-bromopyridyl)]-thiourea":[0],"(CAS":[1],"258340-15-7,":[2],"HI-443)":[3],"is":[4,37],"a":[5,28,42,61],"rationally":[6],"designed":[7],"non-nucleoside":[8],"reverse":[9],"transcriptase":[10],"inhibitor":[11],"(NNRTI)":[12],"with":[13],"potent":[14],"anti-HIV":[15],"activity":[16],"at":[17],"nanomolar":[18],"concentrations":[19],"but":[20],"poor":[21],"oral":[22,48],"bioavailability.":[23],"Here":[24],"the":[25],"identification":[26],"of":[27,35,46],"novel":[29],"oleic":[30],"acid":[31],"containing":[32],"lead":[33],"formulation":[34],"HI-443":[36,59],"described":[38],"which":[39],"resulted":[40],"in":[41,56,67],"approximately":[43],"10-fold":[44,51],"improvement":[45],"its":[47],"bioavailability":[49],"yielding":[50],"higher":[52],"systemic":[53],"exposure":[54],"levels":[55],"mice.":[57,68],"Formulated":[58],"exhibited":[60],"favorable":[62],"pharmacokinetics":[63],"and":[64],"toxicity":[65],"profile":[66]},"counts_by_year":[],"updated_date":"2026-11-05T12:25:35.769452","created_date":"2016-06-24T00:00:00"}